
Nov 16, 2026 · 28 min
Listen from 8:30
Listen at 8:30
Anthropic IPO tests AI trade as Nvidia faces mounting pressure
Anthropic To Become the World’s Most Important AI Stock
Anthropic’s potential offering could reset investor expectations for AI stocks while exposing vulnerabilities across aviation, chip leadership, and pharmaceutical investing.
- 1Anthropic’s potential mega-IPO could become a bellwether for the broader AI investment trade after Nvidia’s recent weakness.
- 2An FAA outage highlights how aging infrastructure and staffing shortages can impose material costs on airlines despite modernization efforts.
- 3AI may lower drug-development costs and accelerate trials, but imperfect biological data complicates its impact on pharma investing.
Don't miss
The episode links Anthropic’s potential IPO to Nvidia’s leadership uncertainty, turning one planned offering into a test of confidence in the AI trade.
The brief
Anthropic’s IPO roadshow arrives as Nvidia faces leadership uncertainty and investor doubts, making the offering a potential bellwether for the broader AI trade.
Carmen Reinicke explains why Anthropic’s deal matters beyond one company, including how it compares with SpaceX’s IPO and could reshape market confidence.
George Ferguson traces an FAA outage to aging infrastructure, difficult upgrades, and staffing shortages, with airline profits potentially falling roughly 10% next quarter.
Nvidia’s board faces pressure over a permanent CEO, while export controls, congressional scrutiny, and alleged chip smuggling and espionage deepen investor concerns.
Sam Fazeli argues that AI is already changing trials, manufacturing, and regulatory work, even as imperfect biological data limits the savings and reshapes pharma M&A.
What was said on this episode
23 statements · 13 positive · 7 negative · 3 neutral
Investors may treat Anthropic as the bellwether for the AI trade.
“Investors might be really ready to sort of step into Anthropic and be watching that as sort of the bellwether of the AI trade.”
Listen at 2:41
Investors will seek a first-day rise in Anthropic stock.
“investors are definitely looking for a first day pop”
Listen at 3:38
Investors want Anthropic stock to continue rising after its debut.
“And then they want to see the stock go up from there.”
Listen at 3:45
Anthropic’s IPO is more than seven times oversubscribed.
“over seven times oversubscribed for this IPO. So a ton of demand.”
Listen at 4:29
Demand for Anthropic shares will likely increase after listing.
“demand will likely just increase.”
Listen at 4:41
Anthropic could join the Nasdaq-100 about three weeks after listing.
“It could be added to the NASDAQ 100 in about three weeks from its public listing.”
Listen at 4:51
OpenAI’s potential public listing appears to be months away.
“Following will be looking for more information to come around OpenAI if they will list when that might be. But that's seemingly months in the future.”
Listen at 6:01
The FAA air-control system was built over 50–60 years or more.
“They've built this air control system over 50, 60 years or more.”
Listen at 9:43
The FAA outage may reduce airline profits by about 10% next quarter.
“it may cost. 10% of profit in the next quarter.”
Listen at 11:30
Fully automated FAA controls will not arrive for a very long time.
“It's not going to happen for a very long time.”
Listen at 12:20
FAA controller recruitment remains deficient.
“I still hear there's deficiencies in controller recruitment.”
Listen at 12:36
NVIDIA dominates AI processors, with no immediate change expected.
“They dominate the market for artificial intelligence processors, and there's no immediate change in that expected.”
Listen at 17:31
NVIDIA executives will face scrutiny over compliance with U.S. chip export controls.
“she is less likely to face as much scrutiny as the former CEO, Jensen Wang, and other officials in the company, including the general counsel, will when it comes to NVIDIA's conduct in terms of compliance with U.S. export controls designed to keep its chips out of Chinese hands.”
Listen at 17:58
AI is already accelerating clinical trials, manufacturing, and regulatory filings.
“AI is being used to speed those things up.”
Listen at 22:14
AI productivity could reduce pharmaceutical R&D costs by 10–20%.
“If you manage to shave off 10 or 20 percent of that cost by increased productivity”
Listen at 22:31
AI can extend effective patent life for some drugs.
“it also gives you the ability to have a longer run on your patent”
Listen at 22:54
AI could increase an obesity drug’s net present value by 20–30%.
“20%, 30% increase in NPV of a product? That could be massive if you're dealing with an obesity drug”
Listen at 23:16
AI performs less reliably in biology because biological data is imperfect.
“the biology is harder because the data is imperfect and i think ai works when your data is good”
Listen at 23:39
Applying AI to biology will take time to produce results.
“it's going to take time”
Listen at 23:53
Pharmaceutical mergers and acquisitions will increase.
“There is going to be more M&A.”
Listen at 25:00
Pharmaceutical companies need biotech assets to strengthen pipelines.
“Pharma companies need these assets.”
Listen at 25:01
AI will accelerate pharmaceutical M&A activity.
“AI is going to help that come faster.”
Listen at 25:20
Healthcare stocks had been significantly depressed until roughly a year ago.
“healthcare had been quite beaten up until about a year or so ago”
Listen at 26:07
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.